Some aspects of the enzymic inactivation of sympathomimetic amines.
This review seeks to discuss the possible importance of monoamine oxidase (MAO) and semicarbazide-sensitive amine oxidase (SSAO) in terminating the effects of released sympathetic transmitters and in the inactivation of endogenous or administered sympathomimetic amines with particular reference to some aspects of the cardiovascular system. Use of in vitro preparations of blood vessels and of other smooth muscles, such as vas deferens and anococcygeus, has thrown light on possible roles for these deaminating enzymes, even in the inactivation of noradrenaline, while the new reversible inhibitors of MAO-A show promise as antidepressants with a reduced risk of hypertensive crises following the ingestion of tyramine-containing food. However, the role of SSAO in the in inactivation of amines remains an enigma, even though much is now known of its biochemical nature. While the pharmacological responses to amine substrates can be potentiated by inhibition of SSAO, there is a suspicion that it is product rather than substrate that is more important.
D006631:Amine Oxidase (Copper-Containing) / Q000037:antagonists & inhibitors / Q000378:metabolism; D000818:Animals; D002394:Catechol O-Methyltransferase / Q000378:metabolism; D002395:Catecholamines / Q000097:blood / Q000378:metabolism; D003641:Deamination; D006801:Humans; D008995:Monoamine Oxidase / Q000378:metabolism; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology; D009474:Neurons / Q000378:metabolism; D012663:Semicarbazides / Q000494:pharmacology; D013564:Sympathetic Nervous System / Q000378:metabolism; D013566:Sympathomimetics / Q000378:metabolism*
D002395:Catecholamines; D008996:Monoamine Oxidase Inhibitors; D012663:Semicarbazides; D013566:Sympathomimetics; C010059:carbamylhydrazine; D006631:Amine Oxidase (Copper-Containing); D008995:Monoamine Oxidase; D002394:Catechol O-Methyltransferase